Rhetoric Doesn't Square With Reality, Sanofi Drug Pricing Report Says
Sanofi said the aggregate US net price of its drugs declined by 11.1% in 2019, while list prices increased 2.9%.
You may also be interested in...
The company released an annual pricing report, showing that Sanofi's US average net prices declined for the fifth year in a row.
Mylan is the first to launch insulin glargine competition in both a vial and pre-filled pen, joining Eli Lilly's Basaglar pen.
A new study looks at list drug price increases and manufacturer discounts over 11 years and finds that despite significant rebates, net price increases still grew 3.5 times more than inflation.